Ocuphire Pharma, Inc.(OCUP)

$1.17—Stale · unknown old

Ask SA Chart

Ocuphire Pharma, Inc.(OCUP)

NASDAQ • Last print unknown ago

$1.17—Stale · unknown old

Ask SA Chart Studio

OCUP(OCUP)

OCUP

9/19/26

Ocuphire Pharma (OCUP)

Saturday

2:39 AM

ThesisRecent clinical trial setbacks and increased competition in the ophthalmology space have led to a more cautious outlook among investors.

Revenue Outlook

Metric	FY2025	FY2026E	FY2027E
Revenue	$0.00	$36M	$61M
Rev. Growth	—	—	+70.5%
EPS	$-0.80	$-0.30	$0.17
EPS Growth	+62.8%	+62.2%	+155%
P/E (fwd)	—	—	7.0×

★ Analysts see FY2027 revenue reaching $61M — +70.5% growth in a single year.

What Could Go Wrong

01Regulatory delays in the approval process could extend the timeline for commercialization, impacting investor sentiment.
02Increased competition from emerging therapies in diabetic retinopathy could pressure market share and pricing.
03Regulatory changes impacting drug approval processes
04Technological advancements in competing therapies
05Emergence of new therapies from larger biotech firms targeting the same indications
06Potential for generic competition once products are approved
07High cash burn rate leading to potential liquidity issues
08Dependence on external funding for ongoing operations

FY2025 Snapshot

Revenue: $0.00
Gross Margin: 0.0%
Op. Margin: 0.0%
Net Margin: 0.0%
Net Income: $-50M
NI Growth: +13.8%
EPS: $-0.80
1Y Return: -19.9%

OCUP Chart

My Notes

"The market is increasingly concerned about the pace of innovation in diabetic retinopathy treatments."
Moat: Ocuphire's focus on niche ophthalmic therapies provides a moderate moat, but the competitive landscape is rapidly evolving.
Watch: The biggest threat is the rapid advancement of competing therapies that could outpace Ocuphire's development timelines.
growth - Investors looking for high-risk, high-reward opportunities in the biotech space.
High interest rates could increase the cost of capital for Ocuphire Pharma, impacting its ability to fund clinical trials and operations…
Watch on earnings: Clinical trial enrollment rates for APX3330, Cash runway based on current burn rate, Market trends in diabetic retinopathy treatments.

One Sentence Summary:

The bear case: regulatory delays in the approval process could extend the timeline for commercialization, impacting investor sentiment.

Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance

Metric

FY2025

FY2026E

FY2027E

—

P/E (fwd)

—

7.0×

What Could Go Wrong

01Regulatory delays in the approval process could extend the timeline for commercialization, impacting investor sentiment.

02Increased competition from emerging therapies in diabetic retinopathy could pressure market share and pricing.

03Regulatory changes impacting drug approval processes

04Technological advancements in competing therapies

05Emergence of new therapies from larger biotech firms targeting the same indications

06Potential for generic competition once products are approved

07High cash burn rate leading to potential liquidity issues

08Dependence on external funding for ongoing operations

My Notes

"The market is increasingly concerned about the pace of innovation in diabetic retinopathy treatments."

Moat: Ocuphire's focus on niche ophthalmic therapies provides a moderate moat, but the competitive landscape is rapidly evolving.

Watch: The biggest threat is the rapid advancement of competing therapies that could outpace Ocuphire's development timelines.

growth - Investors looking for high-risk, high-reward opportunities in the biotech space.

High interest rates could increase the cost of capital for Ocuphire Pharma, impacting its ability to fund clinical trials and operations…

Watch on earnings: Clinical trial enrollment rates for APX3330, Cash runway based on current burn rate, Market trends in diabetic retinopathy treatments.